Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.

Pharmacogenomics - 1 Sept 2014

Sistonen Johanna, Büchel Barbara, Froehlich Tanja K, Kummer Dominic, Fontana Stefano, Joerger Markus, van Kuilenburg André B P, Largiadèr Carlo R

Abstract excerpt

AIM: Decreased DPD activity is a major cause of 5-fluorouracil (5-FU) toxicity, but known reduced-function variants in the DPD gene (DPYD) explain only a part of DPD-related 5-FU toxicities. Here, we evaluated the baseline (pretherapeutic) plasma 5,6-dihydrouracil:uracil (UH2:U) ratio as a marker of DPD activity in the context of DPYD genotypes. MATERIALS & METHODS: DPYD variants were genotyped and plasma U, UH2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antimetabolites, Antineoplastic

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to DPYD gene

Share to Genotype

Share to Uracil

Source

Identifiers

PMID: 25410891
DOI: 10.2217/pgs.14.126

Genes

DPYD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.PMID 25410891Read ↗

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.Semantic proximity Read ↗

DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity Read ↗

Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase.Semantic proximity Read ↗

Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping AssaysSemantic proximity Read ↗

Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.Semantic proximity Read ↗

Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?Semantic proximity Read ↗

Identification of DPYD variants and estimation of uracil and dihydrouracil in a healthy Indian population.Semantic proximity Read ↗

Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.Semantic proximity Read ↗

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper.Semantic proximity Read ↗

Implications of Dihydropyrimidine Dehydrogenase on 5-Fluorouracil Pharmacogenetics and PharmacogenomicsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.